https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25828 Wed 02 Mar 2022 14:24:33 AEDT ]]> Sputum ADAM8 expression is increased in severe asthma and COPD https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17834 Tue 26 Jun 2018 11:21:16 AEST ]]> Soluble RAGE is deficient in neutrophilic asthma and COPD https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21544 Sat 24 Mar 2018 07:50:26 AEDT ]]> Exacerbations of severe asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22192 Sat 24 Mar 2018 07:16:25 AEDT ]]> Working while unwell: workplace impairment in people with severe asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33379 Mon 14 Nov 2022 17:12:48 AEDT ]]> Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26225 Fri 03 Dec 2021 10:33:00 AEDT ]]>